HUTCHMED wins priority review in China for sovleplenib in wAIHA
Bottom line
HUTCHMED said on April 29, 2026, that China’s National Medical Products Administration has accepted its new drug application for sovleplenib in adults with warm antibody autoimmune hemolytic anemia, or wAIHA, and granted the filing priority review. The application covers patients who had an insufficient response to at least one prior glucocorticoid treatment. HUTCHMED said the filing is backed by data from the China Phase II/III ESLIM-02 study, including Phase III topline results announced in January 2026 showing the trial met its primary endpoint of durable hemoglobin response between weeks 5 and 24. The company also said the NMPA granted sovleplenib Breakthrough Therapy Designation for wAIHA in March 2026. (globenewswire.com)
Why it matters: While this is a human hematology story rather than a veterinary medicine development, it’s still relevant to animal health professionals tracking translational immunology and the regulatory momentum behind targeted therapies for immune-mediated blood disorders. Sovleplenib is an oral spleen tyrosine kinase, or Syk, inhibitor, aimed at interrupting Fc receptor and B-cell signaling involved in red blood cell destruction. In Phase II data published in The Lancet Haematology, HUTCHMED reported an overall response rate of 43.8% versus 0% for placebo in the first eight weeks, with a favorable safety profile, underscoring continued industry interest in more targeted alternatives to broad immunosuppression. (globenewswire.com)
What to watch: Next up will be full Phase III data disclosure, including the planned presentation at EHA 2026, and the NMPA’s review timeline under priority review. (globenewswire.com)
HUTCHMED has moved sovleplenib a step closer to market in China, announcing on April 29, 2026, that the NMPA accepted its NDA for warm antibody autoimmune hemolytic anemia and granted the filing priority review. The proposed indication is for adults with wAIHA who have had an insufficient response to at least one prior glucocorticoid treatment. HUTCHMED also disclosed that the program had already received Breakthrough Therapy Designation from the NMPA in March 2026. (globenewswire.com)
The filing builds on a program that has been advancing steadily over the past several years. HUTCHMED initiated the Phase II/III ESLIM-02 study in China in 2022, then moved the registration-stage Phase III portion forward in 2024 to confirm safety and efficacy in adults with primary or secondary wAIHA. In January 2026, the company reported that the Phase III portion met its primary endpoint, defined as durable hemoglobin response during weeks 5 through 24 of treatment, setting up the NDA submission that the company had previously said it planned for the first half of 2026. (hutch-med.com)
Mechanistically, sovleplenib is a selective oral Syk inhibitor. HUTCHMED says that matters in wAIHA because Syk is involved in Fc receptor signaling in phagocytic cells and B-cell receptor signaling, both of which contribute to autoimmune red blood cell destruction. In the Phase II portion of ESLIM-02, later published in The Lancet Haematology in January 2025, the company reported an overall response rate of 43.8% for sovleplenib versus 0% for placebo in the first eight weeks, and 66.7% over 24 weeks including patients who crossed over from placebo, with what it described as a favorable safety profile. (globenewswire.com)
This comes at a time when the wAIHA treatment landscape is becoming more active, even though approved options remain limited. Johnson & Johnson said on April 27, 2026, that the FDA granted Priority Review to nipocalimab for wAIHA in the U.S., calling it the first therapy to receive FDA Priority Review for the condition. That doesn’t directly affect China’s review of sovleplenib, but it does reinforce the broader point that regulators in multiple markets are recognizing the unmet need in wAIHA and moving potentially differentiated therapies onto faster review tracks. (investor.jnj.com)
HUTCHMED has framed sovleplenib as part of a broader hematology and immunology strategy, not a one-off asset. The company noted that this is the second indication for which it has submitted an NDA for sovleplenib, alongside immune thrombocytopenia, where the resubmitted China NDA was accepted with priority review in February 2026. That broader development footprint may matter to clinicians and market watchers because it suggests HUTCHMED is trying to establish sovleplenib as a platform immunology product rather than a narrow single-indication therapy. (globenewswire.com)
Why it matters: For veterinary professionals, the immediate commercial impact is limited because this is a human drug regulatory event in China. Still, the story is useful as a readout on where immune-mediated hematology is heading. Targeted oral agents aimed at specific immune signaling pathways, rather than generalized immunosuppression, continue to gain traction. That’s relevant to veterinarians who manage immune-mediated hemolytic anemia and related disorders in companion animals, because the translational science, trial endpoints, and regulatory interest may help shape future comparative research and industry investment across species. This is an inference based on the mechanism and disease overlap, not a claim that sovleplenib is being developed for veterinary use. (globenewswire.com)
There wasn’t much independent expert commentary available in the immediate reporting around the April 29 announcement, and most coverage traced back to HUTCHMED’s own release. The clearest outside signal of industry reaction is the parallel acceleration of other wAIHA programs, including nipocalimab, which suggests companies and regulators see the space as increasingly actionable after years of limited approved options. (investing.com)
What to watch: The next key milestone is presentation of the Phase III ESLIM-02 data at EHA 2026, followed by any detail from the NMPA on review timing under priority review and, eventually, whether HUTCHMED pursues expansion beyond China. (globenewswire.com)